

James McNamara, Scientific Founder and CEO of Nuclease Probe Technologies
Nuclease Probe Technologies, one of 21 MedTech startup finalists in the 8th annual M2D2 $200K Challenge, was chosen for their development of a novel diagnostic for accurate and early detection of bloodstream infections (BSI’s).
We spoke with Scientific Founder and CEO, James McNamara, who shared the story of their innovation with us.




Nuclease Probe Technologies has raised $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections. 
The
Venture financing is every entrepreneur’s goal— so every entrepreneur needs a plan to get his or her startup to the venture financing stage. That’s why M2D2 is hosting an informative happy hour:
Great news for cost-conscious medical device innovators: M2D2 is waiving the $50 entry fee for the first ten submissions to our 2019 $200K Challenge! Entries are open now—to get your application started, visit